Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FUW-hgp100 + SVGmu
- Development stage
- Preclinical
- Lead developer
- University of Southern California
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
FUW-hgp100 + SVGmu is an **integration-deficient lentiviral vector (IDLV) vaccine** encoding the melanoma antigen human gp100 (hgp100), delivered with a modified Sindbis virus envelope glycoprotein (SVGmu) that specifically targets dendritic cell (DC) surface receptor DC-SIGN. The FUW-hgp100 construct utilizes a mutated HIV-1 integrase (D64V) to prevent vector genome integration, enhancing safety by limiting genomic incorporation. SVGmu pseudotyping enables **selective transduction of DCs**, facilitating antigen delivery and presentation. The platform induces strong antigen-specific CD8 T cell responses and antitumor immunity in preclinical models[1]. This system is developed primarily as a cancer vaccine candidate for melanoma immunotherapy.
- Brand names
- FUW-hgp100 + SVGmu
- Other names
- FUW-hgp100/SVGmuFUW-hgp100/SVGmu(IN−)DC-directed IDLV-FUW-hgp100/SVGmu
02
Targets
DC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin)
Beyond the preview
Go deeper on FUW-hgp100 + SVGmu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FUW-hgp100 + SVGmu.